Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10984957 | 0.86 | NFE2L2 (0.64) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL10984963 | 0.86 | NFE2L2 (0.64) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL566978 | 0.84 | NFE2L2 (0.61) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL280061 | 0.84 | NFE2L2 (0.61) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL29423291 | 0.84 | NFE2L2 (0.61) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL566977 | 0.84 | NFE2L2 (0.61) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL1133764 | 0.84 | NFE2L2 (0.61) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL7312097 | 0.82 | NFE2L2 (0.59) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL9435250 | 0.82 | NFE2L2 (0.59) | NFE2L2MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL10766862 | 0.82 | NFE2L2 (0.59) | NFE2L2MEN1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318085-B2 | Methods and compositions for inhibiting metal corrosion | HALLIBURTON ENERGY SERVICES, INC. (US) | 2012-11-27 | — | — | US | claimed |
| US-20120035086-A1 | Methods and Compositions for Inhibiting Metal Corrosion | HALLIBURTON ENERGY SERVICES, INC. (US) | 2012-02-09 | — | — | US | claimed |
| US-8062586-B2 | Methods and compositions for inhibiting metal corrosion | HALLIBURTON ENERGY SERVICES, INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20100087340-A1 | Methods and Compositions for Inhibiting Metal Corrosion | HALLIBURTON ENERGY SERVICES, INC. | 2010-04-08 | — | — | US | claimed |
| US-20050123437-A1 | Methods and compositions for inhibiting metal corrosion | HALLIBURTON ENERGY SERVICES, INC. | 2005-06-09 | — | — | US | claimed |
| US-20220009153-A1 | COMPOSITION FOR FORMING PATTERN, KIT, CURED FILM, LAMINATE, PATTERN PRODUCING METHOD, AND METHOD FOR MANUFACTURING SEMICONDUCTOR ELEMENT | FUJIFILM CORPORATION (JP) | 2022-01-13 | — | — | US | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| EP-1572113-B1 | CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| EP-1572113-B1 | CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9447100-B2 | Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447100-B2 | Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447100-B2 | Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20010051726-A1 | Method for producing 2-sulfonylpyridine derivatives and method for producing 2- { [ (2-pyridyl) methyl] thio} -1H-benzimidazole derivatives | KURARAY CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6197962-B1 | REACTING A,B-UNSATURATED CARBONYL COMPOUND WITH A SULFONYL CYANIDE; CYCLIZATION | KURARAY CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0931790-A2 | Method for producing 2-sulfonylpyridine derivates and method for producing 2-( (2-pyridyl)methyl)thio)-1H-benzimidazole derivates | KURARAY CO., LTD. (JP) | 1999-07-28 | — | — | EP | disclosed |
| EP-0073301-B1 | PROCESS FOR THE PREPARATION OF ALPHA, BETA AND BETA, GAMMA UNSATURATED KETONES | FIRMENICH SA (CH) | 1984-11-21 | — | — | EP | disclosed |
| US-4453011-A | BASIFICATION OF A DIALLYL CARBINOL | FIRMENICH SA (CH) | 1984-06-05 | — | — | US | disclosed |
| EP-0073301-A1 | Process for the preparation of alpha, beta and beta, gamma unsaturated ketones | FIRMENICH SA (CH) | 1983-03-09 | — | — | EP | disclosed |
| US-4289914-A | FREE RADICAL POLYMERIZATION INITIATORS, CURING AGENTS FOR UNSATURATED POLYESTERS | PENNWALT CORPORATION (US) | 1981-09-15 | — | — | US | disclosed |
| US-4257985-A | Compounds by addition of hydroperoxides to α-β-unsaturated ketones | PENNWALT CORPORATION (US) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051726-A1 | Method for producing 2-sulfonylpyridine derivatives and method for producing 2- { [ (2-pyridyl) methyl] thio} -1H-benzimidazole derivatives | PDXK, KCNJ2, KCNJ1 | NFE2L2 775/4885MEN1 966/4885KMT2A 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.